COVID-19 Factor Wanes But Pharma’s R&D Pipeline Hits Record Heights
Pipeline Breaks 20,000 Barrier
Pharma’s R&D engine has been firing on all cylinders in the past year – pipeline growth in 2021 stood at nearly twice that for the previous year, pushing the number of products under active development over 20,000 for the first time.
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: time runs out to scale the next patent cliff; Novartis searches for new blockbuster; Boehringer Ingelheim’s R&D spending pays off; Shanghai eyes mRNA vaccines as COVID cases rise; and the global pharma R&D pipeline hits new heights.
Blockbusters like Stelara, Eliquis, Prolia and Ibrance are poised to lose US exclusivity over the next five years; pressure is mounting for industry to replenish the portfolio with the next high-growth brands.
China has emerged as a major new force in global pharma R&D amid a "boom" in activity, with not one but two of its companies entering the top 25 by pipeline size for the first time.